Clinical Advisory Council
Cancer care is complex and ever-changing, particularly with recent advances in tumor biology and the development and approval of novel treatments guided by molecular testing. Due to this complexity, a conglomerate of the brightest minds is needed to understand and steer the future of the industry as there is far too much information for any one individual to master. VieCure’s Clinical Advisory Council comprises global leaders from top cancer programs, universities, and institutes who review clinical evidence, evaluate literature, and research Oncology treatments to develop algorithms and codified clinical rules to be actioned within
the VieCure™ A.I. platform.
Why does VieCure need a
Clinical Advisory Council?
-
Assist in creating and updating evidence-based treatment plans, rules, and algorithms for the VieCure clinical inference engine to facilitate cutting-edge point-of-care decision making
-
Analyze de-identified clinical data to expose opportunities such as potential new targets for research and treatment
-
Leverage professional network to improve patient care by providing strategic advice on new directions in cancer care and research across the globe
How will patient's benefit from VieCure's Clinical Advisory Council?
-
Oncologists have access to personalized patient treatment plans based on the most recent
advances in cancer -
Tools within the VieCure platform are used to manage toxicities, monitor treatment compliance, achieve better outcomes and improve quality of life throughout treatment
-
Facilitate ongoing education by providing clinical providers easy access to the most current information regarding the patient’s disease, treatment, and supportive care
Clinical Advisory Council Members
Paul Bunn, MD, FASCO
Distinguished Professor, James Dudley Chair, University of Colorado, Colorado, USA
Jennifer Choi, MD
Chief, Division of Oncodermatology, Robert H. Lurie Comprehensive Cancer Center
Associate Professor, Dermatology, Feinberg School of Medicine, Northwestern University, Illinois, USA
Lisa Madlensky, PhD, CGC
Professor, Molecular Genetics – University of California San Diego, California, USA
William Oh, MD
Chair, the Division of Hematology and Medical Oncology at the Mount Sinai Health System, New York, USA
Ian Olver, MD, PhD, AM
QA Professor (Adjunct), Faculty of Health and Medical Sciences, University of Adelaide, South Australia, Australia
Jai Patel, PharmD,
BCOP, CPP
Chair, Cancer Pharmacology and Pharmocogenomics
Levine Cancer Institute
Atrium Health, Charlotte, North Carolina, USA
Azra Raza, MD
Director, Myelodysplastic Syndrome Center, Department of Medicine, Division of Hematology/Oncology
Professor, Medicine, Columbia University, New York, USA
Max J. Coppes, MD,
PhD, MBA
Nell J. Redfield Chair of Pediatrics at the University of Nevada Reno School of Medicine, Nevada, USA
Pradip De, PhD
Signal Transduction Pathway Consultant – Viecure
Assistant Professor, Department of Internal Medicine at the University of South Dakota, South Dakota, USA
Sashikant Kulkarni, MS, PhD, FACMG
Professor, Molecular and Human Genetics, Baylor College of Medicine, Texas, USA
